Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan

Affiliations

• ¹ Division of Hematology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
• ² Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
• ³ Division of Hematology - Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
• ⁴ Division of Hematology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
• ⁵ Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung, Taiwan.
• ⁶ Division of Hematology - Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
• ⁷ Division of Hematology and Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
• ⁸ Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
• ⁹ Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan.
• ¹⁰ Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi, Taiwan.
• ¹¹ Novartis (Taiwan) Co. Ltd., Taipei, Taiwan.
• ¹² Division of Hematology - Oncology, Department of Internal Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan. Electronic address: cs4816@gmail.com.